Literature DB >> 3778111

Alterations in cerebrospinal fluid concentrations of somatostatinlike immunoreactivity in neuropsychiatric disorders.

G Bissette, E Widerlöv, H Walléus, I Karlsson, K Eklund, A Forsman, C B Nemeroff.   

Abstract

The concentration of somatostatinlike immunoreactivity in cerebrospinal fluid (CSF) from normal, healthy volunteers (n = 10) and patients with DSM-III diagnoses of major depression (n = 17), schizophrenia (n = 11), or dementia (n = 29) was measured by a sensitive and specific radioimmunoassay. Statistically significant decreases in CSF concentrations of somatostatinlike immunoreactivity were seen in all three patient populations when compared with controls. These findings confirm previous reports of decreased concentrations of somatostatinlike immunoreactivity in the CSF of patients with depression and dementia and extend this observation to patients with schizophrenia as well. These findings are concordant with the view that reductions in somatostatinlike immunoreactivity concentrations are associated with diseases in which cognitive function is disturbed.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3778111     DOI: 10.1001/archpsyc.1986.01800120034008

Source DB:  PubMed          Journal:  Arch Gen Psychiatry        ISSN: 0003-990X


  10 in total

1.  Elevated CSF corticotropin-releasing factor concentrations in posttraumatic stress disorder.

Authors:  J D Bremner; J Licinio; A Darnell; J H Krystal; M J Owens; S M Southwick; C B Nemeroff; D S Charney
Journal:  Am J Psychiatry       Date:  1997-05       Impact factor: 18.112

2.  Somatostatin content and receptors in the cerebral cortex of depressed and control subjects.

Authors:  B G Charlton; A Leake; C Wright; A F Fairbairn; I G McKeith; J M Candy; I N Ferrier
Journal:  J Neurol Neurosurg Psychiatry       Date:  1988-05       Impact factor: 10.154

Review 3.  Alterations in neuropeptides in aging and disease. Pathophysiology and potential for clinical intervention.

Authors:  A Leake; I N Ferrier
Journal:  Drugs Aging       Date:  1993 Sep-Oct       Impact factor: 3.923

4.  Decrease in somatostatin-positive cell density in the amygdala of females with major depression.

Authors:  Gaelle Douillard-Guilloux; David Lewis; Marianne L Seney; Etienne Sibille
Journal:  Depress Anxiety       Date:  2016-08-24       Impact factor: 6.505

5.  The influence of human corticotropin-releasing hormone on somatostatin secretion in depressed patients and controls.

Authors:  K P Lesch; E Widerlöv; R Ekman; G Laux; R Rupprecht; H M Schulte; H Beckmann
Journal:  J Neural Transm       Date:  1989       Impact factor: 3.575

6.  Cerebrospinal Fluid Biomarkers in Patients With Unipolar Depression Compared With Healthy Control Individuals: A Systematic Review and Meta-analysis.

Authors:  Ina Viktoria Mousten; Nina Vindegaard Sørensen; Rune Haubo B Christensen; Michael Eriksen Benros
Journal:  JAMA Psychiatry       Date:  2022-06-01       Impact factor: 25.911

7.  Neuropeptides involved in the pathophysiology of schizophrenia and major depression.

Authors:  David De Wied; Hein O. Sigling
Journal:  Neurotox Res       Date:  2002 Aug-Sep       Impact factor: 3.911

Review 8.  Reduced brain somatostatin in mood disorders: a common pathophysiological substrate and drug target?

Authors:  Li-Chun Lin; Etienne Sibille
Journal:  Front Pharmacol       Date:  2013-09-09       Impact factor: 5.810

9.  Association between subclinical hypothyroidism and depression: an updated systematic review and meta-analysis.

Authors:  Huai Heng Loh; Lee Ling Lim; Anne Yee; Huai Seng Loh
Journal:  BMC Psychiatry       Date:  2019-01-08       Impact factor: 3.630

Review 10.  Hypothyroidism and Depression: A Narrative Review.

Authors:  Surya P Nuguru; Sriker Rachakonda; Shravani Sripathi; Mashal I Khan; Naomi Patel; Roja T Meda
Journal:  Cureus       Date:  2022-08-20
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.